Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-rituximab
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-rituximab (also known as 177Lu-DOTA-rituximab) is a CD20-targeted radioimmunotherapy consisting of the chimeric anti-CD20 monoclonal antibody rituximab conjugated to the beta-emitting radionuclide lutetium-177 (177Lu) via a chelator such as DOTA or CHX-A''-DTPA. It is developed for the treatment of CD20-positive B-cell malignancies, including relapsed or refractory follicular lymphoma, mantle cell lymphoma, and other indolent B-cell non-Hodgkin lymphomas (NHL). Upon administration, the antibody binds specifically to CD20 on B-lymphocytes, delivering localized beta radiation that induces DNA damage and cell death in target tumor cells, while minimizing systemic toxicity.
- Other names
- 177Lu-CHX-A''-DTPA-rituximab177Lu-DOTA-rituximab177Lu-DOTA-SCN-rituximab177Lu-labeled rituximab177Lu-Rituximablutetium (177Lu) rituximablutetium-177 DOTA-rituximablutetium177 DOTA-rituximablutetium 177 DOTA-rituximab
02
Targets
Beyond the preview
Go deeper on 177Lu-rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-rituximab.